In breast and ovarian cancer cell lines, high SYCP2 expression correlated with resistance to Cisplatin, a DNA crosslinking agent, and Camptothecin 11 (CPT11, irinotecan), an inhibitor of TOP1 (Fig. 1G). Here, SYCP2 is linked to ovarian carcinoma.